Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b Multi-center, Open Label, Single Arm, 52-week Study, Evaluating the Feasibility, Efficacy and Safety of Rapid Test and Treat Intervention in Newly Diagnosed HIV-1 Infected Adults Using a Fixed Dose Combination of Dolutegravir Plus Lamivudine (DOVATO) as a First Line Regimen

NCT03945981 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.

NCT NCT03945981
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03945981 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b Multi-center, Open Label, Single Arm, 52-week Study, Evaluating the Feasibility, Efficacy and Safety of Rapid Test and Treat Intervention in Newly Diagnosed HIV-1 Infected Adults Using a Fixed Dose Combination of Dolutegravir Plus Lamivudine (DOVATO) as a First Line Regimen
Lead sponsor
ViiV Healthcare
Phase
Phase 3
Overall status
Completed
Start date
July 2, 2019
Completion date
October 20, 2020
Enrollment
131 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections